|
|
Vaccine Detail
|
PD-L1 peptide vaccine |
| Vaccine Information |
- Vaccine Name: PD-L1 peptide vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: PD-L1 peptide (NCT03042793; NCIT_C148146)
- Immunization Route: subcutaneous injection
- Description: This is a vaccine composed of a peptide derived from the tumor-associated antigen (TAA) and immune checkpoint molecule programmed cell death-1 ligand 1 (PD-L1) combined with the immunoadjuvant montanide ISA-51, with potential immunomodulating and antineoplastic activities. Vaccination with PD-L1 peptide vaccine may activate the immune system to induce an immune response against PD-L1-expressing cells. This may increase and restore the proliferation and activation of various immune cells, including cytotoxic T-lymphocytes (CTLs), and may eradicate PD-L1-expressing tumor cells. (NCIT_C148146) The vaccines aims to stimulate PD-L1 specific T-cells, hence eliminating both PD-L1 positive tumor cells as well as PD-L1 positive immunosuppressive and antigen presenting cells in the tumor microenvironment. It has been used in clinical trials for patients with multiple melanoma. (NCT03042793)
|
| Host Response |
|
|
| References |
NCIT_C148146: PD-L1 Peptide Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C148146]
NCT03042793: Vaccination With PD-L1 Peptide Against Multiple Myeloma [https://clinicaltrials.gov/study/NCT03042793]
|
|
